ArticleJournal of clinical medicine2022

Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

Toshihiko Tomita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.